ArticleNPJ primary care respiratory medicine2024
A practical guide to the diagnosis and management of suspected Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) in the United Kingdom.
Article in NPJ primary care respiratory medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Gut-lung axis and microbiome alterations in mycobacterial infections: from pathogenesis to therapeutic potential.Gut microbes · 2026Review
- A review of tigecycline resistance in nontuberculous mycobacteria.Molecular biology reports · 2026Review
- Distribution of Non-Tuberculous Mycobacterium Species in Pulmonary and Extrapulmonary Infections in South India-A Retrospective Analysis.Microorganisms · 2026Article
- Zoonotic Nontuberculous Mycobacteria: Transmission Pathways, Laboratory Diagnosis, Detection Methodologies, and One Health Priorities.Infectious diseases & clinical microbiology · 2026Review
- Real-World Experience of Prolonged Treatment for Treatment-Refractory Nontuberculous Mycobacterial Pulmonary Disease: Benefits and Harms of Extending Therapy beyond 24 Months.Respiration; international review of thoracic diseases · 2026Article
- Performance Evaluation of Targeted Nanopore Sequencing in Non-Tuberculous Mycobacteria Identification: A Comparative Study in Shenzhen, China.Infection and drug resistance · 2026Article
- Pulmonary infection by non-tuberculous mycobacteria in an endemic region for tuberculosis in Northeast Brazil.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Serum HMGB1 and CA19-9 are independently associated with pulmonary cavity formation in patients with non-tuberculous mycobacterial pulmonary disease.American journal of translational research · 2026Article
- Temporal trends, diagnostics, and outcomes of pediatric nontuberculous mycobacterial disease in Slovakia (2017-2024).Frontiers in public health · 2026Article
- Lung microbial dysregulation and TNF inhibition are associated with worsened nontuberculous mycobacterial lung disease.Frontiers in microbiology · 2026Article
- Non-tuberculous mycobacteria (NTM) and COPD: a multicentre prospective study.BMJ open respiratory research · 2025Observational
- Saskemycin, a potent and selective antimycobacterial agent targeting a unique site on the ribosome.Research square · 2025Article
- The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment.Infectious medicine · 2025Review
- Targeting Autophagy as a Strategy for Developing New Host-Directed Therapeutics Against Nontuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2025Review
- Clinical correlation study of non-tuberculous mycobacterial isolates from bronchoalveolar lavage fluid.AMB Express · 2025Article
- Bidirectional pathogenesis between non-tuberculous mycobacteria and bronchiectasis: clinical insights, diagnostic challenges and future directions-Perspectives from South Asia.Frontiers in tuberculosis · 2025Review
- Extrapulmonary Comparisons BetweenInfection and drug resistance · 2025Review
- TIGIT and SNRPA1 as novel diagnostic and predictive biomarkers in obstructive ventilatory dysfunction combined with pulmonary nontuberculous mycobacterial infection patients.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) is a chronic disease characterised by progressive inflammatory lung damage due to infection by non-tuberculous mycobacteria (NTM). Global prevalence of NTM-PD is generally low but is rising, likely due to a combination of increased surveillance, increasing multimorbidity and improved diagnostic techniques. Most disease is caused by Mycobacterium avium complex species. NTM-PD can be challenging to both diagnose and manage but given the risk of untreated disease and the challenges around drug treatments, it is vital that all healthcare professionals involved in primary care consider NTM-PD at the earliest opportunity. In particular, NTM-PD should be considered where there are respiratory symptoms in the setting of pre-existing chronic lung disease such as chronic obstructive pulmonary disease (COPD) and bronchiectasis. Early suspicion should lead to appropriate primary screening measures. This article discusses the relevance of NTM-PD today, risk factors for developing disease, pathways from clinical presentation to referral to specialist care, and discusses management and drug treatments. A flow diagram of a screening process is presented as a guideline for best practice from a United Kingdom perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.